2Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection:findings from the women and infants transmission study. J Infect Dis, 1997, 175:567-575.
3Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternalzidovudine treatment on viral load. JAMA, 1996, 275:599-605.
4Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet, 2000,355:2237-2244.
5Porter K, Wall PG,Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. British Medical Journal, 1993,307:20-23.
6Cartoux M, Meda N, Van de Perre P, et al. Acceptability of voluntary HIV testing by pregnant women in developing countries:an international survey. Ghent International Working Group on Mother-to-child Transmission of HIV AIDS, 1998,12:2489-2493.
7Kind C,Rudin C,Siegrist M, et al. Prenvention of vertical HIV transmission:additive protective effect of elective cesarean section and zidovudine prophylaxis,Swiss National HIV Study Group. AIDS, 1998, 12:205-210.
8Gibb DM , Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus:evidence for preventable peripartum transmission. Lancet, 2000,356:904-907.
9Bucceri AM,Somigliana E, Matrone R, et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod,2002,17:436-441.
10http://www.who.int/reproductive-health/rtis/docs/arvdrugsguidelines.pdf.World Health Organization, Antiretroviral drugs for treating pregnant women and prevention HIV infection in infants:guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings.
